We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.28%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$959M
AUM Growth
+$88.6M
Cap. Flow
-$54.3M
Cap. Flow %
-5.67%
Top 10 Hldgs %
33.04%
Holding
103
New
15
Increased
39
Reduced
35
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$17.6M
2
BSX icon
Boston Scientific
BSX
+$15.7M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.6M
4
MCK icon
McKesson
MCK
+$7.81M
5
FOLD
Amicus Therapeutics
FOLD
+$7.68M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$18.7M
2
LLY icon
Eli Lilly
LLY
+$17.3M
3
THC icon
Tenet Healthcare
THC
+$16.8M
4
RVTY icon
Revvity
RVTY
+$15.2M
5
COO icon
Cooper Companies
COO
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$481B
$48M 5.01%
+80,000
New +$45.8M
BSX icon
2
Boston Scientific
BSX
$71.5B
$42.4M 4.42%
434,377
+151,211
+53% +$15.7M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$29.3B
$40M 4.17%
87,690
-4,648
-5% -$1.89M
PODD icon
4
Insulet
PODD
$9.79B
$35.9M 3.74%
116,238
+10,476
+10% +$3.28M
CVS icon
5
CVS Health
CVS
$122B
$28.6M 2.98%
379,486
-138,321
-27% -$9.48M
KNSA icon
6
Kiniksa Pharmaceuticals
KNSA
$5.93B
$26.1M 2.72%
671,592
+182,796
+37% +$5.94M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.67B
$24.9M 2.6%
1,154,487
-144,338
-11% -$2.6M
ZBH icon
8
Zimmer Biomet
ZBH
$18.4B
$24.8M 2.58%
251,420
+11,025
+5% +$1.09M
SYK icon
9
Stryker
SYK
$130B
$23.7M 2.47%
64,108
+13,732
+27% +$5.31M
QGEN icon
10
Qiagen
QGEN
$8.72B
$22.3M 2.33%
500,159
+2,052
+0.4% +$98.2K
MCK icon
11
McKesson
MCK
$101B
$22M 2.3%
28,542
+11,084
+63% +$7.81M
DHR icon
12
Danaher
DHR
$144B
$21.9M 2.29%
110,541
+451
+0.4% +$89.7K
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$21.1M 2.2%
1,735,003
+1,055,940
+155% +$14.6M
QURE icon
14
uniQure
QURE
$3.22B
$20.2M 2.1%
345,356
-98,066
-22% -$1.78M
NBIX icon
15
Neurocrine Biosciences
NBIX
$16.6B
$19.9M 2.08%
141,822
-24,188
-15% -$3.28M
BIIB icon
16
Biogen
BIIB
$30.7B
$18.2M 1.9%
+130,165
New +$17.6M
MLYS icon
17
Mineralys Therapeutics
MLYS
$2.41B
$17.3M 1.8%
455,523
-8,078
-2% -$175K
UPB
18
Upstream Bio Inc
UPB
$395M
$15.9M 1.66%
843,502
+127,998
+18% +$1.99M
THC icon
19
Tenet Healthcare
THC
$21.1B
$15.1M 1.57%
74,330
-94,554
-56% -$16.8M
XERS icon
20
Xeris Biopharma Holdings
XERS
$1.45B
$14.6M 1.52%
1,791,674
-315,809
-15% -$2.1M
LIVN icon
21
LivaNova
LIVN
$4.2B
$14.4M 1.51%
275,811
+100,811
+58% +$5.07M
MBX
22
MBX Biosciences
MBX
$3.27B
$13.5M 1.41%
773,304
-98,629
-11% -$1.32M
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$13.3M 1.39%
1,687,318
+1,078,681
+177% +$7.68M
DOCS icon
24
Doximity
DOCS
$4.88B
$13.1M 1.37%
178,970
+58,136
+48% +$3.79M
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.82B
$13M 1.36%
846,899
-20,914
-2% -$274K
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Parkman Healthcare Partners held 103 positions worth $959M, up 10% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $54.3M in Q3 2025, closing 12 positions and reducing 35 holdings. Its most notable exit was Verona Pharma, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Parkman Healthcare Partners opened a new position in Biogen worth $18.2M.

  • Parkman Healthcare Partners's largest Q3 2025 buy was Biogen: 130,165 shares worth $18.2M.
  • Parkman Healthcare Partners added most to Boston Scientific in Q3 2025, an estimated $15.7M increase.
  • Parkman Healthcare Partners's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $17.3M.
  • Parkman Healthcare Partners fully exited Verona Pharma in Q3 2025, selling an estimated $18.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $959M portfolio in Q3 2025.
  • Parkman Healthcare Partners opened 15 new positions and closed 12 in Q3 2025.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $959M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.